Stockreport

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

Nanobiotix S.A. - ADSs  (NBTX) 
PDF RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting t [Read more]